The receptor tyrosine kinase ROR1 is a promising therapeutic target for multiple types of lymphoma and leukemia. The extracellular domain of ROR1 is made of three distinct domains, an immunoglobulin-like (Ig) domain, a Frizzled domain (FZD), and a Kringle domain. Antibodies targeting different domains demonstrate a marked difference in therapeutic efficacy when used to treat leukemia cell lines.
ACROBiosystems provides a comprehensive panel of human ROR1 proteins, including those of each aforementioned individual domain for selective targeting. We also offer a prebiotinylated ROR1 ECD protein (Avitag™).
In addition, we also offer ROR1 protein from rodent species, and a complementary set of ROR2 proteins for testing cross-reactivity of anti-ROR1 reagent.
